R&D: Are true drug breakthroughs a thing of the past?

Fierce Biotech

June 2013

One of the most intense discussions at ASCO over the past few days has zeroed in on the FDA's new "breakthrough" drug status. The agency is offering developers essentially an open door at the FDA to any program that qualifies, urging on R&D teams with quick responses and help adapting trials and hurrying the review process with the aim of getting more "transformative" drugs to the market faster.

Read the article here »